CIK 0001818844 · Non-accelerated filer<br>Smaller reporting company
Dogwood Therapeutics, Inc.
Sign in to watch- Ticker
- DWTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 854314201
- Phone
- 8666208655
- Business address
- 44 MILTON AVENUE, ALPHARETTA, GA, 30009
- Former names
- Virios Therapeutics, Inc., Virios Therapeutics, LLC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-10-26 | Sealbond Ltd Director | Grant or award | +4,098,360 | $1.22 | $5.0M | 25,920,693 |
| 2026-06-16 | Keefer David R Director | Grant or award · Stock Option (right to buy) | +16,800 | 16,800 | ||
| 2026-06-16 | De La Rosa Abel Director | Grant or award · Stock Option (right to buy) | +16,800 | 16,800 | ||
| 2026-06-16 | Whitley Richard James Director | Grant or award · Stock Option (right to buy) | +16,800 | 16,800 | ||
| 2026-06-16 | Thomas John C Director | Grant or award · Stock Option (right to buy) | +16,800 | 16,800 | ||
| 2026-03-05 | Duncan Gregory Scott CHIEF EXECUTIVE OFFICER | Grant or award · Stock Option (right to buy) | +330,000 | 330,000 | ||
| 2026-03-05 | Gendreau Roger Michael CHIEF MEDICAL OFFICER | Grant or award · Stock Option (right to buy) | +82,500 | 82,500 | ||
| 2026-03-05 | Grosswald Ralph SVP OF OPERATIONS | Grant or award · Stock Option (right to buy) | +82,500 | 82,500 | ||
| 2026-03-05 | Walsh Angela Chief Financial Officer | Grant or award · Stock Option (right to buy) | +82,500 | 82,500 | ||
| 2025-12-04 | Duncan Gregory Scott CHIEF EXECUTIVE OFFICER | Grant or award · Stock Option (right to buy) | +460,000 | 460,000 | ||
| 2025-12-04 | Gendreau Roger Michael CHIEF MEDICAL OFFICER | Grant or award · Stock Option (right to buy) | +150,000 | 150,000 | ||
| 2025-12-04 | Grosswald Ralph SVP OF OPERATIONS | Grant or award · Stock Option (right to buy) | +150,000 | 150,000 | ||
| 2025-12-04 | Walsh Angela Chief Financial Officer | Grant or award · Stock Option (right to buy) | +150,000 | 150,000 | ||
| 2025-11-21 | Sealbond Ltd Director | Conversion | +21,610,950 | 21,822,333 | ||
| 2025-11-21 | Sealbond Ltd Director | Conversion | +2,842,638 | 2,842,638 | ||
| 2025-11-21 | Sealbond Ltd Director | Conversion · Series A Preferred Stock | −2,161.1 | 0 | ||
| 2025-11-21 | Sealbond Ltd Director | Conversion · Series A-1 Preferred Stock | −284.26 | 0 | ||
| 2025-06-27 | Gendreau Roger Michael CHIEF MEDICAL OFFICER | Grant or award · Stock Option (right to buy) | +12,075 | 12,075 | ||
| 2025-06-27 | Whitley Richard James Director | Grant or award · Stock Option (right to buy) | +2,362 | 2,362 | ||
| 2025-06-27 | Grosswald Ralph SVP OF OPERATIONS | Grant or award · Stock Option (right to buy) | +12,075 | 12,075 |
Page 1 of 6 · 113 trades